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348a Monday, February 17, 2014Ca-activated SPOC conditions: (1) MYBPC3 mutants display depressed
contractility; (2) this effect is independent of the gene variant but is consis-
tent with a mechanism of haplotype insufficiency (rather than ‘‘poison pep-
tide’’ effect); and (3) HCM mutations display different phenotypes when
examined under conditions of low strain.
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While a number of factors underlie cardiac dysfunction in HF, recent atten-
tion has fallen on phosphorylation changes in myofilament proteins, notably
the regulatory proteins. Cardiac myosin regulatory light chain (cMLC2) is a
166 amino acid protein located on the hinge region of myosin heavy chain
and optimally positioned to modulate contraction. Recent studies have shown
that cMLC2v contributes to regulating cardiac pump function and allows for
beat-to-beat tuning of the myosin motor arm. Humans, as well as large ro-
dents such as rabbits, have high sequence homology and a single phosphor-
ylation site at ser15. We hypothesize that human MLC2v phosphorylation is
a critical regulator of myocyte contraction that is dysregulated in HF and
that increasing MLC2v phosphorylation with myosin light chain kinase
(MLCK) can partially reverse the dysfunction seen with HF. Human donor
or HF permeabilized cardiac tissue were incubated with either alkaline phos-
phatase to reduce phosphorylation or PKA to induce maximal phosphoryla-
tion of the other myofilament proteins. Maximal cMLC2v phosphorylation
was then achieved by incubation with MLCK. Force-calcium relationship,
rate of tension redevelopment, tension cost and length dependent activation
was determined. To assess the role of cMLC2v phosphorylation on dynamic
regulation of length dependent activation, intact rabbit cardiomyocytes were
isolated from rabbit hearts and transfected with MLCK to provide maximal
cMLC2v phosphorylation. Cells were then attached using a force transducer
and length controller and a simulated length-force relationship, which
approximate the pressure-volume relationship in vivo, was evaluated at
different diastolic sarcomere lengths. We show that MLC2v phosphorylation
is a critical regulator of myocyte contraction that is dysregulated in the
failing heart and treatment with MLCK can partially reverse the dysfunction
seen with HF.
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Heart failure affects more than 5 million patients in the United States. The
mechanisms by which the heart regulates cross-bridge cycling rate and if
and how such regulation is altered in heart failure are poorly understood.
One possible modulator of this cycling rate is muscle length. In a previously
published study, we showed that the rate of tension redevelopment (ktr) can be
reproducibly measured in intact cardiac trabeculae using a novel approach.
Furthermore, we showed that slacking trabeculae from Lopt corresponding
to end-diastolic volume in vivo) to L90 (corresponding to end-systolic volume
in vivo) increases ktr by about 60%. While this regulation is present in a small
animal model, its role in human myocardium in both health and disease re-
mains unanswered. Therefore, we extended our studies using our novel
method to right ventricular trabeculae isolated from non-failing donor and pa-
tients with heart failure. The failing samples had preserved length-tension
relationship, reduced force-frequency relationship, and b-adrenergic desensiti-
zation as compared to non-failing donors. Contractile and relaxation kinetics
of twitch of both non-failing and failing trabeculae were slowed down with
increasing muscle length from L90 to Lopt. We were able to reproducibly mea-
sure ktr in intact human cardiac trabeculae; ktr during maximal myofilament
activation in both non-failing and failing samples decreased with increasing
muscle length. This effect of muscle length on ktr was also present at sub-
maximal activation. These effects can be potentially due to post-
translational modifications. We have preliminary ktr data after rapid length
changes during maximal activation and PKA/PKCBII inhibition at maximal
and sub-maximal activation levels. The overall data provides evidence that
muscle length can regulate cross-bridge cycling kinetics in both non-failing
and failing human hearts.1757-Pos Board B487
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Background and Rationale: we have previously shown that the myocardium
of patients with Hypertrophic Cardiomyopathy (HCM) shows increased CaM-
KII activity with respect to non-HCM non-failing surgical patients (controls).
We found higher phosphorylation levels of several tested CaMKII targets,
such as L-Type Ca2þ channels, Naþ channels and phospholamban (Coppini
et al., Circulation 2013). Such changes are likely to determine significant dele-
terious effects on the electrical and mechanical function of HCM
myocardium.
Methods: we assessed the effects of a selective inhibitor of CaMKII, the cell-
permeant Autocamtide-related Inhibitory Peptide II (AIP-II), on force and
intracellular Ca2þ in intact trabeculae and cardiomyocytes isolated from surgi-
cal septal samples of HCM patients who underwent myectomy.
Results: HCM trabeculae display an increased diastolic tension and a slower
kinetics of isometric force generation when compared to control trabeculae.
AIP-II determines a reduction of diastolic tension, with larger effects at fast
pacing rates (1353 % at 2Hz). Additionally, AIP-II accelerated the kinetics
of force generation in HCM muscles (time to peak contraction at 1Hz:
255517 ms at baseline vs. 232510 ms with AIP-II, p<0.05). Accordingly,
in HCM cardiomyocytes AIP-II lowered intracellular diastolic Ca2þ levels
(from 278 5 40 nM to 159 5 28 nM, p<0.01) and reduced the frequency-
dependent increase of diastolic [Ca2þ]. The kinetics of Ca2þ transients, how-
ever, were not significantly affected by AIP-II. This suggests that reduced
CaMKII phosphorylation of myofilament proteins may underlie the acceler-
ated contractile kinetics observed in HCM trabeculae following AIP-II
exposure.
Discussion: The results indicate that increased activation of CaMKII plays a
significant role in determining the abnormalities of myocardial contraction in
HCM. Pharmacological inhibition of CaMKII may represent a viable option
to reduce diastolic dysfunction in HCM patients.
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Mutations in cardiac troponin T (cTnT) have been linked to hypertrophic car-
diomyopathy (HCM). Previous experiments in our lab utilizing a novel cTnT
R92L transgenic mouse model revealed an allosterically mediated decrease in
the PKA phosphorylation potential of cardiac troponin I (cTnI). We hypoth-
esized the cTnT R92L mutation causes a change in the dynamics of the N-
terminal extension, hindering the availability of PKA substrates S23/S24 on
cTnI. In the current study this hypothesis was tested both in silico and
in vitro. First, molecular dynamics (MD) simulations using our all-atom
thin filament model in the Ca2þ saturated state were performed. MD pre-
dicted an approximately 7A˚ narrowing between the N-terminal extension
of cTnI and cardiac troponin C (cTnC). To experimentally evaluate the in-
silico predictions, Fo¨rster Resonance Energy Transfer (FRET) experiments
were conducted on fully reconstituted thin filaments. The cTnI was labeled
with the FRET donor AEDANS at three sites on the N-terminal extension
of cTnI. The acceptor DDPM, was labeled on six sites on cTnC. Steady state
and time resolved FRET experiments were performed in the presence and
absence of the TnT R92L mutation. Both theoretical and experimental ap-
proaches revealed that in the presence of the cTnT R92L mutation the dy-
namics of cTnI was allosterically altered. The N-terminal extension of
cardiac troponin I moved closer to the N-domain of cTnC. This anharmonic
fluctuation likely hinders the availability of the PKA substrate sites and leads
to the observed blunting of the beta-adrenergic response in animal models
and human patients.
